Session outline
•Introduction to psychoses.
•Assessment of psychoses.
•Management of psychoses.
•Follow-up.
•Review.
Q7. SCOPING QUESTION: In adults with moderate-severe depressive disorder, what is the effectiveness and safety of antidepressant medication (ADM) in comparison with psychological treatment?
The WHO mhGAP programme’s existing guidelines recommend that either structured brief psychological treatm...ents (e.g., interpersonal psychotherapy or cognitive behavioural therapy, including behavioural activation) or antidepressant medication (e.g., SSRIsi and tricyclic antidepressants) be considered in adults with moderate-severe depression. Health care workers need to know whether these treatments have different effects, including side-effects, in treating depressive disorder in the short and long term, in order to improve clinical decision-making.
more
Q5.SCOPING QUESTION: In individuals with psychotic disorders (including schizophrenia) who require long-term antipsychotic treatment, what is the safety and role of depot antipsychotic medication?
The new guide provides practical, first-line management recommendations for mental, neurological and substance use conditions. Contents include modules on assessing and managing conditions such as acute stress, grief, moderate-severe depressive disorder, post-traumatic stress disorder, epilepsy, and... harmful use of alcohol and drugs.
more
В этом разделе «Руководства mhGAP по принятию мер в отношении психических и неврологических расстройств» приведены рекомендации по оценке и оказанию помощи при ост...ом стрессовом расстройстве, посттравматическом стрессовом расстройстве и горе в неспециализированных медицинских учреждениях. Он представляет собой приложение к «Руководству mhGAP попринятию мер в отношении психических и не-
врологических расстройств и расстройств, связанных с употреблением наркотиков и других веществ, в неспециализированных медицинских учреждениях» (ВОЗ, 2010 г.). Руководящие принципы, отраженные в этом разделе, основаны на официально утвержденных рекомендациях группы по разработке руководства ВОЗ.
more
Q15. SCOPING QUESTION: Is pharmacological intervention effective and safe for treatment of psychotic disorders in adolescents (including schizophrenia and bipolar disorder)?
It includes different activities for the different material provided in mhGAP
Session Outline
•General Principles
•Essentials of mental health care and clinical practice: Assessments
•Essentials of mental health care and clinical practice: Management
•Essentials of mental health care and clinical practice: Follow-up
•Reviews
DEP supporting material
• Person stories
• Role plays – role plays 3 and 4 are extra material for
supplementary activities
• Multiple choice questions
• Video links
This module aims to provide basic guidance on management of range of mental health complaints not coveredelsewhere in this guide. Some of these complaints may be similar to depression, but upon closer examamination are distinct from the conditions covered in this guide. Other mental health complaint...s are considered significant when they impair daily functioning or when the person seeks help for them. Other mental health complaints can be due to stress.
more
SUI supporting material
• Person stories
• Role plays
• Multiple choice questions
• Video link
Session outline
•Introduction to dementia
•Assessment of dementia
•Management of dementia
•Follow-up
•Review
SUI supporting material
• Person stories
• Role plays
• Multiple choice questions
• Video link
Activity 2: mhGAP SUI module – assessment and management
Q12. SCOPING QUESTION: In people with psychotic disorders, including schizophrenia and bipolar disorder, are recovery-oriented strategies enhancing vocational and economic inclusion (such as supported employment) feasible and effective?
“mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings” is a technical tool for implementation of the mhGAP Programme. The Intervention Guide has been developed through a systematic review of evidence, followed by an international consul...tative and participatory process. It provides the full range of recommendations to facilitate high quality care at first- and second-level facilities by the non-specialist health-care providers in resource-poor settings
more
This module should always be used together with the
mhGAP Intervention Guide for Mental, Neurological
and Substance Use Disorders in Non-specialized Health
Settings (WHO, 2010), which outlines relevant general
principles of care and management of a range of other
mental, neurological and substa...nce use disorders.
(www.who.int/mental_health/publications/mhGAP_
intervention_guide/en/index.html)
In the future, this module may be integrated with other
products in the following ways:
– This module may be integrated – in its full form –
into future iterations of the existing mhGAP Intervention
Guide.
– The module will be integrated –in a simplified structure –
into a new product, the WHO-UNHCR mhGAP Intervention
Guide for Humanitarian Settings (planned for 2014).
more
What can you expect?
As a future facilitator your role will be to learn about the structure of mhGAP-IG, how to teach the materials and utilize opportunities to prastice facilitation and supervision skills.
As a supervisor your role will be to serve as a point of reference for non-specialized heal...th-care providers, supporting them in providing service for individuals with MNS disorders in non-specialized health settings.
more
Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?